Actualización del cáncer gástrico

Gastric cancer (GC) is the fifth most frequently diagnosed malignant tumor worldwide and is the fourth leading cause of death due to cancer. There are different risk factors that predispose individuals to its onset. Most cases are sporadic, although between 5%–10% of cases have familial aggregation. Histologically, more than 90% are adenocarcinomas. It should be managed through a multidisciplinary approach. In localized and locally advanced stages, a perioperative chemotherapy strategy has been shown to be effective in several randomized studies. In disseminated disease, combinations of chemotherapy with or without immunotherapy are currently used, as well as the combination with trastuzumab in tumors that overexpress HER2 (human epidermal growth factor receptor 2).